shadow_tr

The People of Tulane Cancer Center Research


Yan_12_24_16Yan Dong, Ph.D.
Professor, Department of Structural and Cellular Biology
Tulane Cancer Center Program Member

Contact Information
Email: ydong@tulane.edu
Phone: 504-988-4761
Address: 1430 Tulane Ave., Box SL-49, New Orleans, LA 70112-2699


Biographical Narrative

Dr. Dong received her Ph.D. in experimental pathology from the State University of New York at Buffalo in 2000. From 2000 - 2002, she was a postdoctoral fellow in cancer chemoprevention at Roswell Park Cancer Institute. She became a research assistant professor in 2002 and an assistant professor in 2005 in the Cancer Chemoprevention Department. In November 2007, Dr. Dong joined the faculty of Tulane University School of Medicine as an assistant professor in the Department of Structural and Cellular Biology.

Research Interests
Dr. Dong has a long-standing interest in prostate cancer, particularly in altered androgen receptor signaling in castration-resistant prostate cancer and mechanisms and efficacies of candidate prostate cancer interventions.  Disease progression after hormone therapies is the most critical challenge in the clinical management of prostate cancer.  Accumulating evidence indicates that prostate cancers can adapt to all current hormone therapies by signaling through androgen receptor splice variants that lack the ligand-binding domain and are constitutively active.  We are currently characterizing how these splice variants are generated and their mechanisms of action.  We are also developing drugs/regimens to inhibit these splice variants for more effective treatment of advanced prostate cancer.

Selected Publications

Y Zhan, G Zhang, X Wang, Y Qi, S Bai, D Li, T Ma, O Sartor, EK Flemington, H Zhang, P Lee, and Y Dong. (2017) Interplay between cytoplasmic and nuclear androgen receptor splice variants mediate castration resistance. Molecular Cancer Research, 15, 59-68. PMID: 27671337. Featured in the "Molecular Cancer Research Highlights: Selected Articles from This Issue" with a figure.

S Cao, Y Zhan, and Y Dong. (2016) Emerging data on androgen receptor splice variants in prostate cancer. Endocrine-Related Cancer, Invited review. 23:T199-T210. PMCID:PMC5107136. Featured in “Uro Today”.

D Xu, Y Zhan, Y Qi, B Cao, S Bai, W Xu, SS Gambhir, P Lee, O Sartor, EK Flemington, H Zhang, CD Hu, and Y Dong.  (2015) Androgen receptor splice variants dimerize to transactivate target genes. Cancer Research, 75, 3663-3671. PMCID:PMC4558376. Featured in “MDLinx”, “Just Cancer News”, “BioWorld from Thomson Reuters”.  Editorial: Emmanuel S. Antonarakis and Jun Luo. (2015) AR splice variant dimerization - clinical implications Nature Reviews Urology, 12, 431-433.

B Cao, Y Qi, G Zhang, D Xu, Y Zhan, X Alvarez, Z Guo, X Fu, SR Plymate, O Sartor, H Zhang, and Y Dong. (2014) Androgen Receptor Splice Variants Activating the Full-Length Receptor in Mediating Resistance to Androgen-Directed Therapy.  Oncotarget, 5, 1646-56.  PMCID:PMC4039237.

Y Zhan, B Cao, Y Qi, S Liu, Q Zhang, W Zhou, D Xu, H Lu, O Sartor, W Kong, H Zhang, and Y Dong. (2013) Methylselenol Prodrug Enhances MDV3100 Efficacy for Treatment of Castration-Resistant Prostate Cancer.  International Journal of Cancer, 133, 2225-33.  PMCID:PMC3750963.  Featured in “MDLinx”.

B Cao, X Liu, J Li, S Liu, Y Qi, Z Xiong, A Zhang, T Wiese, X Fu, J Gu, PS Rennie, O Sartor, BR Lee, C Ip, L Zhao, H Zhang, and Y Dong. (2013) 20(S)-Protopanaxadiol-aglycone Downregulation of the Full-length and Splice Variants of Androgen Receptor.  International Journal of Cancer, 132, 1277–1287.   PMCID:PMC3509250.



 

1430 Tulane Ave, New Orleans, LA 70112 medsch@tulane.edu